mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

@article{GrzybowskaIzydorczyk2012mTORKI,
  title={mTOR kinase inhibitors as a treatment strategy in hematological malignancies.},
  author={Olga Grzybowska-Izydorczyk and Piotr Smolewski},
  journal={Future medicinal chemistry},
  year={2012},
  volume={4 4},
  pages={487-504}
}
The mammalian target of rapamycin (mTOR) kinase is a key element of intracellular signal transduction, responsible for the regulation of cell growth and proliferation. Since abnormal activation of the mTOR pathway was found in several tumors, including human malignancies, it may be an attractive target for antineoplastic treatment. The first identified mTOR inhibitor was rapamycin (sirolimus). Subsequently, the most potent rapamycin analogues (rapalogues), such as everolimus, temsirolimus and… CONTINUE READING